Federal Register / Vol. 60, No. 41 / Thursday, March 2, 1995 / Notices 11671

(Catalog of Federal Domestic Assistance No.

83.516, Disaster Assistance.)

James L. Witt,

Director.

[FR Doc. 95–5156 Filed 3–1–95; 8:45 am]

BILLING CODE 6718–02–M

[FEMA–1044–DR]

Amendment to Notice of a Major

Disaster Declarations; CA

AGENCY: Federal Emergency

Management Agency (FEMA).

ACTION: Notice.

SUMMARY: This notice amends the notice

of a major disaster for the State of

California, (FEMA–1044–DR), dated

January 10, 1995, and related

determinations.

EFFECTIVE DATE: February 21, 1995.

FOR FURTHER INFORMATION CONTACT:

Pauline C. Campbell, Response and

Recovery Directorate, Federal

Emergency Management Agency,

Washington, DC 20472, (202) 646–3606.

SUPPLEMENTARY INFORMATION: The notice

of a major disaster for the State of

California dated January 10, 1995, is

hereby amended to include the

following areas among those areas

determined to have been adversely

affected by the catastrophe declared a

major disaster by the President in his

declaration of January 10, 1995:

The counties of El Dorado, Madera, and

Solano for Individual Assistance and Public

Assistance.

(Catalog of Federal Domestic Assistance No.

83.516, Disaster Assistance)

Richard W. Krimm,

Associate Director, Response and Recovery

Directorate.

[FR Doc. 95–5155 Filed 3–1–95; 8:45 am]

BILLING CODE 6718–02–M

FEDERAL MARITIME COMMISSION

Ocean Freight Forwarder License

Applicants

Notice is hereby given that the

following applicants have filed with the

Federal Maritime Commission

applications for licenses as ocean freight

forwarders pursuant to section 19 of the

Shipping Act of 1984 (46 U.S.C. app.

1718 and 46 CFR 510).

Persons knowing of any reason why

any of the following applicants should

not receive a license are requested to

contact the Office of Freight Forwarders,

Federal Maritime Commission,

Washington, DC 20573.

MSL Express Inc., 160–19 Rockaway

Boulevard C, Jamaica, NY 11434,

Officers: Chester Tong, President, Lily

Tong, Vice President

New K.S.A.I. Inc., 9009 La Cienega

Boulevard, Inglewood, CA 90301,

Officers: Kunihiro Iwahashi,

President, Satoshi Hattori, Treasurer

Dated: February 27, 1995.

By the Federal Maritime Commission.

Joseph C. Polking,

Secretary.

[FR Doc. 95–5124 Filed 3–1–95; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL RESERVE SYSTEM

Eastside Holding Corporation, et al.;

Formations of; Acquisitions by; and

Mergers of Bank Holding Companies

The companies listed in this notice

have applied for the Board’s approval

under section 3 of the Bank Holding

Company Act (12 U.S.C. 1842) and §

225.14 of the Board’s Regulation Y (12

CFR 225.14) to become a bank holding

company or to acquire a bank or bank

holding company. The factors that are

considered in acting on the applications

are set forth in section 3(c) of the Act

(12 U.S.C. 1842(c)).

Each application is available for

immediate inspection at the Federal

Reserve Bank indicated. Once the

application has been accepted for

processing, it will also be available for

inspection at the offices of the Board of

Governors. Interested persons may

express their views in writing to the

Reserve Bank or to the offices of the

Board of Governors. Any comment on

an application that requests a hearing

must include a statement of why a

written presentation would not suffice

in lieu of a hearing, identifying

specifically any questions of fact that

are in dispute and summarizing the

evidence that would be presented at a

hearing.

Unless otherwise noted, comments

regarding each of these applications

must be received not later than March

27, 1995.

A. Federal Reserve Bank of Atlanta

(Zane R. Kelley, Vice President) 104

Marietta Street, N.W., Atlanta, Georgia

30303:

1. Eastside Holding Corporation,

Snellville, Georgia; to become a bank

holding company by acquiring 100

percent of the voting shares of The

Eastside Bank & Trust Company,

Snellville, Georgia.

B. Federal Reserve Bank of

Minneapolis (James M. Lyon, Vice

President) 250 Marquette Avenue,

Minneapolis, Minnesota 55480:

1. Guaranty Development Company,

Livingston, Montana; to acquire 100

percent of the voting shares of American

Bank (Whitefish), Whitefish, Montana.

Board of Governors of the Federal Reserve

System, February 24, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–5118 Filed 3–1–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 94E–0360]

Determination of Regulatory Review

Period for Purposes of Patent

Extension; Albunex

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) has determined

the regulatory review period for

Albunex and is publishing this notice

of that determination as required by

law. FDA has made the determination

because of the submission of an

application to the Commissioner of

Patents and Trademarks, Department of

Commerce, for the extension of a patent

which claims that medical device.

ADDRESSES: Written comments and

petitions should be directed to the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

rm. 1–23, 12420 Parklawn Dr.,

Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:

Brian J. Malkin, Office of Health Affairs

(HFY–20), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–443–1382.

SUPPLEMENTARY INFORMATION: The Drug

Price Competition and Patent Term

Restoration Act of 1984 (Pub. L. 98–417)

and the Generic Animal Drug and Patent

Term Restoration Act (Pub. L. 100–670)

generally provide that a patent may be

extended for a period of up to 5 years

so long as the patented item (human

drug product, animal drug product,

medical device, food additive, or color

additive) was subject to regulatory

review by FDA before the item was

marketed. Under these acts, a product’s

regulatory review period forms the basis

for determining the amount of extension

an applicant may receive.

A regulatory review period consists of

two periods of time: A testing phase and

an approval phase. For medical devices,

the testing phase begins with a clinical

investigation of the device and runs

until the approval phase begins. The